Literature DB >> 18356269

N-Demethylation is a major route of 2-amino-3-methylimidazo[4,5-f]quinoline metabolism in mouse.

Vijaya M Lakshmi1, Fong Fu Hsu, Terry V Zenser.   

Abstract

2-Amino-3-methylimidazo[4,5-f]quinoline (IQ) metabolism was evaluated in mouse to better understand its tumorigenicity. Urinary metabolites from mice orally administered 40 mg/kg [(14)C]IQ were compared with those from similarly treated rats. The recovery of radioactivity was significantly greater in mouse urine. The relative proportion of metabolites was significantly different, and a new rodent metabolite was detected. For rat, the proportion of previously identified metabolites excreted was 5-O-glucuronide > sulfamate > 5-sulfate > N-glucuronide. In mouse urine, a new metabolite, demethyl-IQ, represented approximately 26% of IQ metabolism with the proportion of metabolites as follows: 5-O-glucuronide > demethyl-IQ > sulfamate > N-glucuronide > 5-sulfate. Mouse metabolites were identified by electrospray ionization mass spectrometry. Demethyl-IQ was shown to be 2-aminoimidazo[4,5-f]quinoline. N-Acetyl-2-amino-3-methylimidazo[4,5-f]quinoline was not detected with mice. Mouse liver slices produced 5-O-glucuronide, demethyl-IQ, and sulfamate with the former two being significantly reduced by ellipticine. Liver microsomes only produced demethyl-IQ. Ellipticine, a cytochrome P450 1A inhibitor, but not furafylline, an 1A2 selective inhibitor, prevented microsomal N-demethylation. Inhibitors had similar effects on 7-ethoxyresorufin O-deethylation activity. Demethyl-IQ was not further metabolized by an intact mouse or liver microsomes. Thus, mouse IQ metabolism is significantly different from that in rat, and these differences may affect IQ tumorigenicity. N-Demethylation of IQ-like heterocyclic amines occurs in mouse, monkey, and human but not in rat.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356269      PMCID: PMC2654388          DOI: 10.1124/dmd.107.019166

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  36 in total

1.  The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis.

Authors:  H S Cooper; L Everley; W C Chang; G Pfeiffer; B Lee; S Murthy; M L Clapper
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

2.  A balance study of 14C-labelled 3H-imidazo[4,5-f]quinolin-2-amines (IQ and MeIQ) in rats.

Authors:  P Sjödin; M Jägerstad
Journal:  Food Chem Toxicol       Date:  1984-03       Impact factor: 6.023

3.  A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions.

Authors:  R J Pohl; J R Fouts
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

4.  Differential distribution of the mixed-function oxidase activities in rabbit kidney.

Authors:  T V Zenser; M B Mattammal; B B Davis
Journal:  J Pharmacol Exp Ther       Date:  1978-12       Impact factor: 4.030

5.  Metabolism of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in human hepatocytes: 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid is a major detoxification pathway catalyzed by cytochrome P450 1A2.

Authors:  S Langouët; D H Welti; N Kerriguy; L B Fay; T Huynh-Ba; J Markovic; F P Guengerich; A Guillouzo; R J Turesky
Journal:  Chem Res Toxicol       Date:  2001-02       Impact factor: 3.739

6.  Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation.

Authors:  H S Cooper; S Murthy; K Kido; H Yoshitake; A Flanigan
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

7.  Autoradiographic distribution of 14C-labeled 3H-imidazo[4,5-f]quinoline-2-amines in mice.

Authors:  K Bergman
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

8.  Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat.

Authors:  Kaoru Kobayashi; Kikuko Urashima; Noriaki Shimada; Kan Chiba
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

9.  Genotoxicity of the food mutagen 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and analogs.

Authors:  W S Barnes; C A Lovelette; C Tong; G M Williams; J H Weisburger
Journal:  Carcinogenesis       Date:  1985-03       Impact factor: 4.944

10.  Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis.

Authors:  Yasuhiro Masubuchi; Toshiharu Horie
Journal:  Drug Metab Dispos       Date:  2004-04       Impact factor: 3.922

View more
  4 in total

1.  The C8-2'-deoxyguanosine adduct of 2-amino-3-methylimidazo[1,2-d]naphthalene, a carbocyclic analogue of the potent mutagen 2-amino-3-methylimidazo[4,5-f]quinoline, is a block to replication in vitro.

Authors:  Plamen P Christov; Goutam Chowdhury; Craig A Garmendia; Feng Wang; James S Stover; C Eric Elmquist; Albena Kozekova; Karen C Angel; Robert J Turesky; Michael P Stone; F Peter Guengerich; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

Review 2.  Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines.

Authors:  Robert J Turesky; Loic Le Marchand
Journal:  Chem Res Toxicol       Date:  2011-06-20       Impact factor: 3.739

3.  Characterization of new metabolites from in vivo biotransformation of 2-amino-3-methylimidazo[4,5-f]quinoline in mouse by mass spectrometry.

Authors:  Fong-Fu Hsu; Vijaya M Lakshmi; Terry V Zenser
Journal:  J Mass Spectrom       Date:  2009-09       Impact factor: 1.982

4.  Identification of new 2-amino-3-methylimidazo[4,5-f]quinoline urinary metabolites from beta-naphthoflavone-treated mice.

Authors:  Vijaya M Lakshmi; Fong-Fu Hsu; Terry V Zenser
Journal:  Drug Metab Dispos       Date:  2009-05-18       Impact factor: 3.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.